Aroa Biosurgery Limited (ASX: ARX) - ETF Exposure

Current share price for ARX : $0.570 0.01 (1.72%)⁺

Aroa Biosurgery Limited (ARX) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a soft-tissue regeneration company that develops, manufactures and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction.

ARX General Information ⁺

ASX Code	ARX
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	197
ARX Share Price	$0.570
Day High	$0.580
Day Low	$0.570
Last Close	$0.580
ARX Share Price Movement	$0.01 ( 1.72% )

Prices as at 16:40, 21 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to ARX

Aroa Biosurgery Limited (ARX) is held across 1 ETF spanning strategies that include biotechnology exposure . Its weighting in those funds means performance can have an outsized influence - when ARX moves, funds like DACE that hold it can move with it.

For more concentrated exposure, ETFs such as DACE (Dimensional Australian Core Equity (Managed Fund)) allocate about 0% to ARX , while the average exposure across all 1 ETF that hold it is around 0% .

Top ETF holdings

Dimensional Australian Core Equity (Managed Fund) (DACE) ~ 0%

Last updated: ETF data and holdings as at 20 August 2026

Own ARX directly or through an ETF?

How does holding Aroa Biosurgery Limited (ARX) shares directly compare to ETFs that include it?

	ARX Direct	DACE ASX
Holdings	1 company	470 holdings
ARX Weight	100%	0%
Diversification	Single Stock	Broad
Annual Cost	Brokerage only	0.28% p.a.
Approx. Yield	0%	2.95%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not ARX's direct yield. Annual cost uses each ETF's MER.

ARX Exposure on $10,000 investment

How a $10,000 investment in Aroa Biosurgery Limited (ARX) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Aroa Biosurgery Limited (ARX)	Direct share	$0.570	-3.39%	-$339	$9,661
Dimensional Australian Core Equity (Managed Fund) (DACE)	Equity - Australia Strategy	$19.340	-0.36%	-$36	$9,964

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Aroa Biosurgery Limited (ARX) ETFs

1 ETF hold Aroa Biosurgery Limited (ARX).

ETF	ARX Weight	MER	Yield
Dimensional Australian Core Equity (Managed Fund) (DACE)	0%	0.28%	2.95%

Aroa Biosurgery Limited (ARX) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Aroa Biosurgery Limited (ARX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Aroa Biosurgery Limited (ARX) price-sensitive announcements

ARX - FY26 Full Year Results Presentation

The FY26 Full Year Results Presentation for Aroa Biosurgery Limited focuses on financial p

Aroa Biosurgery Limited (ARX)
26 May 2026 | 8:51 AM

ARX - FY26 Appendix 4E and Full Year Results

Aroa Biosurgery Limited, a company specializing in soft-tissue regeneration, announced its

Aroa Biosurgery Limited (ARX)
26 May 2026 | 8:48 AM

ARX - ARX FY26 Preliminary Results

Aroa Biosurgery Limited has announced preliminary unaudited results for the fiscal year en

Aroa Biosurgery Limited (ARX)
30 Apr 2026 | 8:24 AM

ARX - Symphony Randomised Control Trial Complete

Aroa Biosurgery Limited announced the completion of its Symphony randomised controlled tri

Aroa Biosurgery Limited (ARX)
30 Mar 2026 | 9:15 AM

Aroa Biosurgery Limited (ARX) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID	Health Care	$197	Final Director's Interest Notice - JD	21 Aug 2026 10:45AM	$0.575	$0.570	fallen by 0.87%
Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID	Health Care	$197	Results of Annual General Meeting	19 Aug 2026 2:33PM	$0.575	$0.570	fallen by 0.87%
Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID	Health Care	$197	CEO Presentation - AGM	19 Aug 2026 8:51AM	$0.580	$0.570	fallen by 1.72%
Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID	Health Care	$197	Chairman's Address - AGM	19 Aug 2026 8:44AM	$0.580	$0.570	fallen by 1.72%
Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID	Health Care	$197	Notification of cessation of securities - ARX	12 Aug 2026 9:50AM	$0.605	$0.570	fallen by 5.79%
Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID	Health Care	$197	Notification regarding unquoted securities - ARX	12 Aug 2026 9:50AM	$0.605	$0.570	fallen by 5.79%

ARX Financial Summary

Year to Mar	NPAT	EPS	EPS chg (%)	PER	Yield (%)	Franking (%)
2028F	C2	$1.70	100.00%	34.90	0.00%	0.0%
2027F	C2	$0.80	-27.20%	69.90	0.00%	0.0%
2026A	$4.14	$1.10	-214.00%	54.00	0.00%	0.0%

ARX Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
Aroa Biosurgery Limited (ARX)	$201M	-2.1400	-0.2719	1.0120	50.8772	69.8795	34.7305	0.00%	0.00%	0.00%
CSL Limited (CSL)	$79,729M	0.7309	-0.4960	-0.0142	10.3138	20.4619	20.7560	2.55%	2.28%	2.27%
Clinuvel Pharmaceuticals Limited (CUV)	$524M	0.0287	0.0000	0.0000	14.4847	0.0000	0.0000	0.48%	0.00%	0.00%
Mesoblast Limited (MSB)	$3,078M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,722M	-1.3893	0.0000	-0.1440	0.0000	278.8079	325.7253	0.00%	0.00%	0.00%

ARX Directors

Name	Position	Start Date
Mr Brian Roderick Ward	Chief Executive Officer, Managing Director	21 Sep 2007
Mr James (Jim) Neil McLean	Non-Executive Chairman, Non-Executive Director	10 Aug 2011
Mr Philip John McCaw	Non-Executive Director	5 Mar 2008
Mr Paul N Shearer	Non-Executive Director	31 Oct 2025
Dr Catherine Mohr	Non-Executive Director	1 Nov 2022
Ms Darla Hutton	Non-Executive Director	22 Mar 2024

Aroa Biosurgery Limited (ARX) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
26 Jun 2026	DIDDAMS, John	Sell	Indirect Shares	200,000	$0.629	$125,789.040
6 Jun 2025	DIDDAMS, John	Sell	Indirect Shares	160,000	$0.484	$77,474.960
30 Sep 2024	MOHR, Catherine	Buy	Indirect Shares	436,364	$0.375	$163,453.670

See all changes in directors' interest & trades for Aroa Biosurgery Limited (ARX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ARX Management

Name	Position
James Blair Agnew	Chief Financial Officer,Joint Company Secretary
Yasmin Winchester	Chief of Technical Operations
Rod Stanley	Chief Operating Officer
Dr. Barnaby May	Chief Scientific Officer
Tracy Weimar	Joint Company Secretary

ARX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Aroa Biosurgery Limited (ARX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
33,125,800 (9.58%)	Brian Ward
30,421,199 (8.79%)	FirstCape Group Limited
29,842,804 (7.57%)	Acorn Capital Limited
20,077,154 (5.80%)	Phil McCaw
17,288,432 (5%)	State Street Australia Ltd

ARX Calendar of Events

Date	Event
29 June 2027	Report (Annual)
25 May 2027	Report (Prelim)
24 November 2026	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us